Key result
Oral dapsone (50 mg/kg/day) had little positive effect on healing doxorubicin extravasation ulcers in a rat model.
Why the study?
Does oral dapsone improve healing of doxorubicin extravasation ulcers in a rat model?
Does oral dapsone improve healing of doxorubicin extravasation ulcers in a rat model?
Oral dapsone does not appear to be effective in treating doxorubicin extravasation injuries in a rat model.
Answers are grounded in this paper and cite their sources.
Does not support dapsone for doxorubicin extravasation ulcers; leaves open human translation and alternative therapies.
Doxorubicin is the most common antitumor drug implicated in serious extravasation injuries. Progressive tissue necrosis may lead to intense pain, chronic ulceration, and disfiguring tissue loss. This progressive necrosis is analogous to that seen with brown recluse spider bites, where dapsone is an established mode of therapy, minimizing the area of tissue loss by a proposed antiinflammatory mechanism. The backs of 50 Lewis rats were injected intradermally with 1 mg of doxorubicin in 1 cc of saline to simulate an extravasation injury. The rats were divided into five groups for treatment with oral dapsone 50 mg/kg/day: 10 were controls (no treatment), 10 were started the day before injury, 10 were started the day of injury, 10 were started the day after injury, and 10 were started 1 week after injury. The area of ulceration was calculated by planimetry. The data suggest that dapsone has little positive effect on healing extravasation ulcers.
No takes yet. Share an insight, caveat, or question.
Sommer et al. (2002) studied Doxorubicin extravasation injury (n=50). Oral dapsone vs. No treatment was evaluated on Area of ulceration calculated by planimetry. Oral dapsone (50 mg/kg/day) had little positive effect on healing doxorubicin extravasation ulcers in a rat model.
Synapse has enriched 10 related papers. Consider them for comparative context: